Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

121.95
Delayed Data
As of Feb 23
 +0.59 / +0.49%
Today’s Change
60.30
Today|||52-Week Range
125.49
+21.62%
Year-to-Date
3 All-or-Nothing Stocks We're Closely Watching
Feb 23 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Present...
Feb 15 / Zacks.com - Paid Partner Content
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Bioscienc...
Feb 22 / GuruFocus News - Paid Partner Content
Why Agenus Stock Is Surging Today
Feb 14 / MotleyFool.com - Paid Partner Content
Troubling Trial Data Weighed on Agenus Inc Stock Today
Feb 22 / MotleyFool.com - Paid Partner Content
Lilly's Olumiant Gets Marketing Authorization in Europe
Feb 14 / Zacks.com - Paid Partner Content
What's Driving Lilly's (LLY) Shares after 2016 Decline?
Feb 16 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant ...
Feb 14 / Zacks.com - Paid Partner Content
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
Feb 15 / Zacks.com - Paid Partner Content
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
Feb 13 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close121.36
Today’s open121.40
Day’s range118.79 - 122.14
Volume1,568,082
Average volume (3 months)1,381,140
Market cap$23.0B
Dividend yield--
Data as of 4:00pm ET, 02/23/2017

Growth & Valuation

Earnings growth (last year)+1,700.00%
Earnings growth (this year)--
Earnings growth (next 5 years)+95.15%
Revenue growth (last year)+46.70%
P/E ratio154.4
Price/Sales17.60
Price/Book--

Competitors

 Today’s
change
Today’s
% change
MYLMylan NV+0.33+0.79%
VRTXVertex Pharmaceutica...-0.06-0.07%
ZTSZoetis Inc+0.20+0.37%
BAXBaxter International...+0.33+0.66%
Data as of 4:01pm ET, 02/23/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)$0.44
Annual revenue (last year)$1.1B
Annual profit (last year)$104.2M
Net profit margin9.43%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts


Search for Jobs